Modulate Therapeutics

Modulate Therapeutics Overview

Founded 2015
Status Private
Latest Deal Type Series A
Investors 2

Modulate Therapeutics General Information


Developer of drugs designed to treat neoplastic disease. The company's drugs increase the presence of tumor infiltrating lymphocytes while blocking a key mediator of immuno-suppression in the tumor micro-environment for patients suffering from different cancer indications, enabling healthcare providers to improve the lives of the cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Montreal, Quebec
  • Canada
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Modulate Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 01-Feb-2016 Completed Startup
1. Joint Venture Completed Startup

Modulate Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Mark Cipriano Chief Financial Officer
Brian Horsburgh Ph.D Chief Executive Officer

Modulate Therapeutics Board Members (1)

Name Representing Role Since
Luc Marengère Ph.D TVM Capital Life Science Board Member 000 0000

Modulate Therapeutics Investors (2)

To view Modulate Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
TVM Capital Life Science Venture Capital Majority 000 0000 000000 0
Immunova Corporation Majority 000 0000 000000 0

Ready to get started?

Request a free trial